MELATONIN IN DEVELOPMENT OF PATIENTS WITH COPD INSOMNIA: NEYROIMMUNOENDOKRINNY ASPECT

The study included 102 people with a diagnosis of COPD stage II-III. It was noted that the sleep quality in elderly patients with COPD have a significant negative impact floor (F = 14,79; p = 0,0002), age (F = 11,66; p = 0,0011), smoking (F = 8 19; p = 0,0054), duration of disease (F = 9,88; p = 0,0024), the number of exacerbations, need to consult a specialist in a year (F = 13,38; p = 0,0005), the number of hospitalizations annually (F = 8,29; p = 0,0052). Research quality of sleep disorders in patients with COPD older at entry into the study revealed in all patients with stage II COPD (100.0 %) and in all patients with COPD stage III (100.0 %) insomnia. After 12 months of follow-up in residential COPD patients with stage II sleep quality disturbances that against the background of traditional therapy of COPD received 4 courses for 14 days during the 12 months of melatonin at a dose of 3 mg for 30-40 minutes before going to bed, found a significant positive dynamics a number of the parameters studied when compared with older patients with COPD stage II with the quality of sleep disorders, who received only traditional treatment of COPD. Appointment of melatonin in therapeutic doses helps eliminate insomnia in patients with COPD stage II on the background of the classical medical approach to prevent violation of the daily regime of the body and biorhythm.